Zurich (awp) – The Swiss Stock Exchange started Monday’s session on the right foot, encouraged by the recovery on Wall Street. Two weeks before the inauguration of future American president Donald Trump, investors mainly had macroeconomic data to analyze.
The New York Stock Exchange ended higher on Friday evening, driven by renewed appetite for risk. The Dow Jones rose by 0.80%, the Nasdaq index by 1.77% and the broader S&P 500 index by 1.26%.
In China, growth in the services sector rebounded in December to its highest level in seven months, according to the Purchasing Managers’ Activity Index (PMI) for services, calculated by S&P Global and the business media. Chinese Caixin.
In Switzerland, retail turnover took advantage of the rising cost phenomenon to increase by 0.8% in November year-on-year, excluding the effects of working days and public holidays.
Investors will also be watching the PMI index in the euro zone and inflation in Germany this Monday.
“European indices should open higher this morning, in the wake of Wall Street closing which rebounded after five consecutive sessions of decline,” estimated John Plassard. But for the Mirabaud Banque expert, “the questions concerning political questions in Europe and the United States two weeks before the inauguration of Donald Trump could reverse the trend”.
Around 9:06 a.m., the flagship SMI index rose 0.23% to 11,650.30 points, after closing the first session of the year on Friday with an increase of 0.20%. The SLI accelerated by 0.38% to 1928.63 points and the SPI gained 0.30% to 15,565.58 points.
In a business news situation still in a state of complete calm after the end-of-year holidays, the majority of star stocks were moving in the green.
The largest increases were recorded by VAT Group (+2.2%), UBS Group (+1.5%) and Partners Group (+1.5%), without specific information.
At the other end of the table were Sandoz Group (-0.9%), Lindt (-0.5%) and ABB (-0.5%). The electrical engineering giant was penalized by a lowering of recommendation to “underperform”, compared to “market perform” previously, and of the price target by Berstein SG.
On the broader market, DocMorris (-4.5%) was shunned by investors, after several lowering of the price target.
Cicor (-0.3%) has finalized the acquisition of the German service provider for the development and manufacturing of electronic modules and systems Profectus.
Santhera (+3.0%) was on the contrary sought after. The laboratory has extended the geographic distribution of its Duchenne muscular dystrophy treatment Agamree (vamorolone) to new, unspecified countries.
al/cw
